Angioside: The role of Angiogenesis and Hypoxia in Lung Neuroendocrine Tumours According to Primary Tumour Location in Left or Right Parenchyma.
angiogenesis
hypoxia
left side
lung NET
necrosis
neuroendocrine tumours
prognostic factors
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
09 Oct 2022
09 Oct 2022
Historique:
received:
02
09
2022
revised:
03
10
2022
accepted:
05
10
2022
entrez:
14
10
2022
pubmed:
15
10
2022
medline:
15
10
2022
Statut:
epublish
Résumé
Well-differentiated lung neuroendocrine tumours (Lu-NETs), classified as typical (TC) and atypical (AC) carcinoids, represent 30% of NETs. Angiogenesis plays an essential role in NET development and progression. A higher vascular network is a marker of differentiation, with positive prognostic implications. Materials and Methods: We retrospectively evaluated microvessel density (MVD) by CD34 immunohistochemical (IHC) staining and hypoxia by IHC staining for Hypoxia-inducible factor 1α (HIF-1α), comparing right- and left-lung parenchyma in 53 lung NETs. Results: The median age was 66 years (39−81), 56.6% males, 24.5% AC, 40.5% left-sided tumours and 69.8% TNM stage I. The mitotic count was <2/10 per 10 HPF in 79.2%, and the absence of necrosis in 81.1%, 39.6% with Ki67, was ≤2%. The MVD, the number of vessels and the average vessel area median values were significantly higher in the right than the left parenchyma (p: 0.025, p: 0.019, p: 0.016, respectively). Hypoxia resulted present in 14/19 (73.6%) left tumours and in 10/20 (50%) right tumours in the parenchyma (p: 0.129). Conclusions: This study suggests a biological rationale for a different angiogenesis and hypoxia according to the Lu-NETs’ location. In our study, left primary tumours were less vascularized and most likely to present hypoxia than right primary tumours. This finding could have potentially useful prognostic and predictive implications for Lu-NETs.
Identifiants
pubmed: 36233825
pii: jcm11195958
doi: 10.3390/jcm11195958
pmc: PMC9570740
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : research was partially funded by a grant from the Italian Ministry of Education, Research and University (PRIN 2017Z3N3YC).
ID : PRIN 2017Z3N3YC
Références
Neuroendocrinology. 2018;107(4):355-365
pubmed: 30244255
Ann Oncol. 2015 Sep;26(9):1987-1993
pubmed: 26063633
Clin Cancer Res. 2019 Jun 15;25(12):3486-3494
pubmed: 30833272
J Natl Cancer Inst. 2001 Feb 21;93(4):309-14
pubmed: 11181778
Thorac Cardiovasc Surg. 2016 Mar;64(2):159-65
pubmed: 25756243
J Clin Oncol. 2002 Jun 1;20(11):2633-42
pubmed: 12039924
Lung India. 2021 Mar-Apr;38(2):134-138
pubmed: 33687006
Nature. 2000 Sep 14;407(6801):249-57
pubmed: 11001068
J Thorac Cardiovasc Surg. 2002 Feb;123(2):303-9
pubmed: 11828290
Clin Cancer Res. 2008 Nov 15;14(22):7272-83
pubmed: 19010843
Genes Dev. 2001 Apr 1;15(7):807-26
pubmed: 11297505
Ann Diagn Pathol. 2017 Aug;29:11-16
pubmed: 28807335
Sci Rep. 2016 Feb 25;6:19857
pubmed: 26912193
Microsc Res Tech. 2003 Feb 1;60(2):181-5
pubmed: 12539172
Eur J Cancer. 2013 Dec;49(18):3780-7
pubmed: 24012098
J Clin Oncol. 2008 Jun 20;26(18):3063-72
pubmed: 18565894
Neuroendocrinology. 2019;108(2):109-120
pubmed: 30485860
N Engl J Med. 2011 Feb 10;364(6):501-13
pubmed: 21306237
Hum Pathol. 2004 Jul;35(7):825-31
pubmed: 15257545
Neoplasma. 2015;62(3):478-83
pubmed: 25866229
Histopathology. 2000 Jan;36(1):8-16
pubmed: 10632746
Int J Mol Sci. 2012;13(2):1444-1460
pubmed: 22408401
Ann Thorac Surg. 2020 Apr;109(4):1009-1018
pubmed: 31706866
Ann Oncol. 2015 Aug;26(8):1604-20
pubmed: 25646366
Hum Pathol. 2003 Jan;34(1):18-27
pubmed: 12605362
BMC Cancer. 2012 Nov 12;12:514
pubmed: 23146028
J Cancer. 2019 Jul 10;10(18):4226-4236
pubmed: 31413741
J Thorac Dis. 2017 Nov;9(Suppl 15):S1442-S1447
pubmed: 29201447
Cancer. 2008 Jul 1;113(1):5-21
pubmed: 18473355
Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):E864-73
pubmed: 26831065
Nat Rev Cancer. 2002 Jan;2(1):38-47
pubmed: 11902584
Lancet Oncol. 2020 Nov;21(11):1500-1512
pubmed: 32966811
J Cardiothorac Surg. 2016 Mar 02;11:35
pubmed: 26935588
Am J Clin Pathol. 2014 Sep;142(3):320-4
pubmed: 25125621
Clin Cancer Res. 2010 Jan 15;16(2):420-9
pubmed: 20068079
Endocrine. 2022 Apr;76(1):208-217
pubmed: 35088292
Br J Cancer. 2005 Jan 17;92(1):94-101
pubmed: 15558070
J Thorac Oncol. 2008 Nov;3(11):1213-23
pubmed: 18978555
Ann Oncol. 2012 Oct;23 Suppl 7:vii120-3
pubmed: 22997444
Neuroendocrinology. 2020;110(5):393-403
pubmed: 31422400
BMC Cancer. 2014 Mar 14;14:184
pubmed: 24628963
Hum Pathol. 2002 Feb;33(2):175-82
pubmed: 11957142
Endocr Relat Cancer. 2009 Sep;16(3):967-76
pubmed: 19502452
Endocrine. 2022 Jun;76(3):733-746
pubmed: 35301675
Cancer. 2007 Apr 15;109(8):1478-86
pubmed: 17340592
Cancer. 2003 Feb 15;97(4):934-59
pubmed: 12569593
Asian Cardiovasc Thorac Ann. 2021 Jul;29(6):532-540
pubmed: 33853389
J Thorac Cardiovasc Surg. 2018 Jan;155(1):405-413
pubmed: 28986041
J Clin Oncol. 2021 Jul 10;39(20):2304-2312
pubmed: 33945297
Chin Med J (Engl). 2012 Sep;125(17):3022-6
pubmed: 22932173
Acta Oncol. 2018 Aug;57(8):1109-1116
pubmed: 29463166
Virchows Arch. 2021 Jan;478(1):5-19
pubmed: 33474631
Am J Surg Pathol. 2009 Apr;33(4):626-32
pubmed: 19065104
JAMA Oncol. 2017 Oct 01;3(10):1335-1342
pubmed: 28448665
Nat Med. 2006 Jan;12(1):122-7
pubmed: 16341243